Galectin Therapeutics (GALT) Short-Term Debt issuances (2022 - 2026)

Galectin Therapeutics' Short-Term Debt issuances history runs 5 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $257000.0 in Q1 2026; TTM through Mar 2026 was $10.3 million, a 48.72% decrease from a year earlier, with the FY2025 full-year figure at $21.0 million, down 30.0% from the prior year.
• Short-Term Debt issuances declined to $257000.0 in Q1 2026 per GALT's latest filing, from $10.0 million in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $10.0 million in Q4 2022 and bottomed at $257000.0 in Q1 2026.
• The 5-year median for Short-Term Debt issuances is $10.0 million (2022), against an average of $8.5 million.
• Across the five-year window, Short-Term Debt issuances changed 0.0% in 2023 and sank 50.0% in 2025, its largest moves.
• Year by year, Short-Term Debt issuances stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then tumbled by 97.43% to $257000.0 in 2026.
• Per Business Quant, the three latest GALT Short-Term Debt issuances figures stand at $257000.0 (Q1 2026), $10.0 million (Q4 2025), and $5.0 million (Q2 2025).